Table 2

Comparison of variables between participants with both baseline and 6-month follow-up values

DomainData available n=Baseline6-month follow-upP value
Falls risk
 Fear of falling, n (%)400.10
    None/mild (1–2)8.0 (20.0)14.0 (35.0)
    Moderate (3)24.0 (60.0)19.0 (47.5)
    High (4)8.0 (20.0)7.0 (17.5)
 Risk factors for falls
    Orthostatic hypotension10424 (23.1)12 (11.5) 0.002
    Depression10218 (17.7)12 (11.8)0.07
    Proprioceptive*10386 (83.5)85 (82.5)1.00
    Dizziness10326 (25.2)18 (17.5)0.06
    Vasovagal symptoms or signs1008 (8.0)1 (1.0) 0.02
    Visual impairment10494 (90.4)100 (96.2) 0.03
    Hearing impairment10164 (63.4)63 (62.4)1.00
    Malnutrition risk10126 (25.7)25 (24.8)1.00
Sarcopenia
  Met criteria, n (%)10583.0 (78.3)79.0 (74.5)0.51
Biochemical measures (IQR)
  Albumin (g/L)5443 (41–45)42 (40–44) 0.046
  Corrected calcium (mmol/L)412.4 (2.3–2.4)2.4 (2.3–2.4)0.31
  Creatinine (nmol/L)5480 (70–90)80 (70–95)0.46
  eGFR (mL/min)5465.5 (56, 78)64 (54–82)0.22
  Hb (g/L)53132 (126–142)132 (127–143)0.30
  Vitamin D (nmol/L)5163 (48–78)65 (54–83)0.32
  PTH (pmol/L)436.9 (4.2–9.5)6.6 (4.7–10.8)0.48
  TSH (mlU/L)441.5 (0.9–2.0)1.6 (0.8–2.1)0.15
  • Bold p values indicate significant difference between baseline and 6-month follow-up measures.

  • *Proprioceptive and vestibular abnormalities.

  • Sarcopenia criterion is fulfilling at least two of the following criteria: gait velocity <0.8 m/s, grip strength <20 kg (females) and <30 kg (males) and appendicular lean mass/height2<5.5 kg/m2 (females) or <7.26 kg/m2 (males).

  • BMD, bone mineral density (femoral neck); eGFR, estimated glomerular filtration rate;  Hb, haemoglobin; PTH, parathyroid hormone; TSH, thyroid-stimulating hormone.